RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Core Insights - RenovoRx, Inc. is set to host its third quarter 2025 financial results and business highlights conference call on November 13, 2025, at 4:30 p.m. ET [1][3] - The management will discuss developments related to the RenovoCath device commercialization and ongoing clinical trials, including the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer [2][5] Company Overview - RenovoRx is a life sciences company focused on developing targeted oncology therapies and commercializing the RenovoCath device, which is FDA-cleared for local drug delivery [4][6] - The company utilizes a patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform designed to deliver therapeutics directly to tumor sites, potentially reducing systemic toxicity [4][6] Clinical Trials and Product Development - The company is evaluating a novel drug-device combination product candidate, intra-arterial gemcitabine (IAG), in the ongoing Phase III TIGeR-PaC trial [5][6] - IAG has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, granting seven years of market exclusivity upon FDA approval [6] Commercialization Efforts - RenovoRx is actively commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath devices as of December 2024 [7] - The company is expanding its customer base, including high-volume National Cancer Institute-designated centers, and is exploring further revenue-generating activities [7]